A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis

Journal of the American Academy of Dermatology

Volumn 63, Issue 6, 2010, Pages 984-990

  Rook, Alain H ^a   Wood, Gary S ^b   Duvic, Madeleine ^c   Vonderheid, Eric C ^d   Tobia, Alfonso ^e   Cabana, Bernard ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d DREXEL UNIVERSITY   (United States)

^e Hy BioPharma Inc   (United States)

Author keywords

Cutaneous T cell lymphoma; Hypericin; Phototherapy; Psoriasis

Indexed keywords

HYPERICIN; PLACEBO;

ADULT; AGED; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PHOTOSENSITIVITY REACTION; APPLICATION SITE PRURITUS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IRRADIATION; LIGHT IRRADIANCE; MALE; MULTICENTER STUDY; MYCOSIS FUNGOIDES; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SKIN DEFECT; THERAPY EFFECT; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LIGHT; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PLACEBOS; PSORIASIS; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650298649     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.02.039     Document Type: Article

References (18)

1. P.A. Bunn Jr., S.J. Hoffman, D. Norris, L.E. Golitz, and J.L. Aeling Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome) Ann Intern Med 121 1994 592 602
2. R.D. Bigler, P. Crilley, B. Micaily, L.W. Brady, D. Topolsky, and S. Bulova Autologous bone marrow transplantation for advanced stage mycosis fungoides Bone Marrow Transplant 7 1991 133 137
3. S.J. Graham, R.W. Sharpe, S.M. Steinberg, J.D. Cotelingam, E.A. Sausville, and F.M. Foss Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome Cancer 72 1993 726 734
4. S. Broder, R.L. Edelson, M.A. Lutzner, D.L. Nelson, R.P. MacDermott, and M.E. Durm The Sézary syndrome: a malignant proliferation of helper T cells J Clin Invest 58 1976 1297 1306
5. P.A. Bunn Jr., and S.I. Lamberg Report of the committee on staging and classification of cutaneous T-cell lymphomas Cancer Treat Rep 63 1979 725 728
6. J.A. Parrish, T.B. Fitzpatrick, L. Tanenbaum, and M.A. Pathak Photochemotherapy of psoriasis and oral methoxsalen and long-wave ultraviolet light N Engl J Med 219 1974 1207 1211
7. A. Patapenko Mechanism of photodynamic effects of furocoumarins J Photochem Photobiol 9 1991 1 33
8. R.S. Stern, K.T. Nichols, and L.H. Väkevä Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet light A radiation (PUVA): the PUVA follow-up study N Engl J Med 336 1997 1041 1045
9. C. Thomas, R.S. MacGill, G.C. Miller, and R.S. Pardini Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinoxidase. Photochem Photobiol 55 1 1992 47 53
10. D. Meruelo, G. Lavie, and D. Lavie Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin Proc Natl Acad Sci U S A 85 1988 5230 5234
11. G. Lavie, F. Valentine, B. Levin, Y. Mazur, G. Gallo, and D. Lauie Studies of the mechanism of action of the antiretroviral agents hypericin and pseudohypericin Proc Natl Acad Sci U S A 86 1989 5963 5967
12. F.E. Fox, Z. Niu, A. Tobia, and A.H. Rook Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders J Invest Dermatol 111 1998 327 332
13. K. Kalka, H. Merk, and H. Mukhtar Photodynamic therapy in dermatology J Am Acad Dermatol 42 2000 389 416
14. L.R. Braathen, R.-M. Szeimies, N. Basset-Seguin, R. Bissonnette, P. Foley, and D. Pariser Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus J Am Acad Dermatol 56 2007 125 143
15. J. Wu, M. Nihal, J. Siddiqui, E.C. Vonderheid, G.S. Wood, and J. Wu Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation J Invest Dermatol 129 2009 1165 1173
16. E. Contassot, K. Kerl, S. Roques, R. Shane, O. Gaide, and M. Dupuis Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression Blood 111 2008 4780 4787
17. M. Blank, M. Mandel, Y. Keisari, D. Meruelo, and G. Lavie Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin Cancer Res 63 2003 8241 8247
18. W.T. Couldwell, R. Gopalakrishna, D.R. Hinton, S. He, M.H. Weiss, and R.E. Law Hypericin: a potential antiglioma therapy Neurosurgery 35 1994 705 709